This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Practical Psychopharmacology

Ketamine for Depression, 5:

Potential Pharmacokinetic and Pharmacodynamic Drug Interactions

Chittaranjan Andrade, MD

Vertical divider

ABSTRACT

Ketamine, administered in subanesthetic doses, is gaining recognition as an off-label treatment for severe and even treatment-refractory depression. This article explores potential pharmacokinetic and pharmacodynamic drug interactions of relevance to the use of ketamine in depression. Sparse evidence suggests that ketamine will not induce clinically significant drug interactions except to the extent that these are predictable by its clinical actions. A small body of literature indicates that drugs that induce cytochrome P450 (CYP)2B6 and CYP3A4 will reduce exposure to ketamine and that drugs that inhibit these enzymes will increase exposure to ketamine. Common genetic polymorphisms of the CYP2B6 gene may also be associated with variations in the exposure to ketamine. However, the clinical implications of such variations in exposure have not been sufficiently studied. A very small number of reports and studies suggest that concurrent benzodiazepine medication may diminish the antidepressant benefits of ketamine. Likewise, a small body of literature suggests that drugs (such as lamotrigine) that inhibit glutamatergic signaling may reduce the adverse effects of ketamine; however, it is unknown whether these drugs also diminish the antidepressant effect. Data from clinical trials indicate that most conventional antidepressants can probably be combined with ketamine without compromising efficacy or increasing the adverse effect burden.

J Clin Psychiatry 2017;78(7):e858–e861

https://doi.org/10.4088/JCP.17f11802

Introduction

Previous articles in this column considered issues related to the efficacy, adverse effects, and possible mechanism(s) of action of ketamine in the treatment of depression1; discussed indications and contexts for the use of ketamine as an off-label antidepressant2; evaluated the antidepressant benefits and risks of R-ketamine, S-ketamine, and racemic ketamine3; and reviewed issues related to dosing, rate of administration, route of administration, duration of treatment, and frequency of sessions when ketamine is used in subanesthetic doses to treat depression.4 The present article examines potential pharmacokinetic and pharmacodynamic interactions when ketamine is used as an off-label treatment for depression.

The Effect of Ketamine on Cytochrome P450 (and Other) Metabolic Enzymes and Their Substrates

In vivo studies in a rodent model found that a single dose of ketamine had no effect on cytochrome P450 (CYP)1A, CYP2B/2C, and 2E1 enzymatic activity; however, there was mild (13%) and possibly clinically nonsignificant inhibition of the activity of CYP2D1 and mild to modest (18%–32%) inhibition of CYP3A.5,6 Ketamine-induced reduction in CYP3A4 activity may involve an inhibition of CYP3A4 gene expression.7 Contradicting these findings, in another rodent study, after 14 days of continuous gastric infusion with ketamine 50 mg/kg, induction of the activity of the CYP enzymes 1A2, 2B6, and 3A4 was observed.8

Given the contradictory findings, the small magnitude of the inhibition described, the prolonged megadosing required for enzyme induction, the absence of report of enzyme modulation in human studies, and the low doses and brief and infrequent occasions of use, it is unlikely that ketamine would cause clinically significant pharmacokinetic interactions when used in subanesthetic doses for the treatment of depression.

Ketamine is also used off label to treat pain, and depression that arises in the context of pain.9–11 In this context, it may inhibit the glucuronidation of morphine (in patients who are also receiving this drug for pain management), as suggested by the results of an in vitro study.12 There is no information available, so far, on whether this interaction is clinically significant.

The Effect of Cytochrome P450 Enzyme Modulators on Ketamine Pharmacokinetics

Ketamine undergoes N-demethylation to norketamine.13 In an in vitro study, the CYP2B6, CYP2C9, and CYP3A4 enzymes, in that order, showed the highest metabolic activity for both R- and S- enantiomers of ketamine.13,14 However, given the relative content of these P450 isoforms in human liver, CYP3A4 may be the most important enzyme involved in ketamine N-demethylation at therapeutic concentrations of the drug.13

Rifampicin. In a study15 conducted in 20 healthy human volunteers, rifampicin, which potently induces CYP3A4 and CYP2B6, reduced the area under the curve (AUC) of the plasma concentrations of S-ketamine and S-norketamine by 10% and 50%, respectively. A compartmental analysis suggested increases of 13% and 200% in the elimination of S-ketamine and S-norketamine from their respective central compartments.15

Itraconazole and ticlopidine. Emphasizing the importance of CYP2B6 in the metabolism of ketamine, a placebo-controlled crossover study16 in 11 healthy volunteers found that the CYP2B6 inhibitor ticlopidine more than doubled the AUC of oral S-ketamine (0.2 mg/kg), whereas the CYP3A inhibitor itraconazole, unexpectedly, had no effect.

Macrolide antibiotics. In a placebo-controlled crossover randomized controlled trial (RCT) conducted in 10 healthy volunteers, 4 days of pretreatment with clarithromycin was associated with a 3.6-fold increase in the peak concentration (Cmax) of oral S-ketamine (0.2 mg/kg) and a 2.6-fold increase in the AUC. Clarithromycin also increased the self-rated drug effect.17 Logically, erythromycin (but not azithromycin), which also inhibits CYP3A4, could be expected to have a similar effect.

Grapefruit juice. Grapefruit juice inhibits CYP3A4 and can thereby increase the bioavailability of substrates of this enzyme by decreasing the metabolism of the substrates in the intestinal lining at the time of absorption as well as by decreasing the metabolism of the substrates in the liver, and elsewhere, after absorption.18 In a randomized crossover trial in 12 healthy volunteers, 5 days of intake of grapefruit juice (200 mL thrice per day) trebled the AUC of oral S-ketamine (0.2 mg/kg), doubled the Cmax, and increased the elimination half-life of the drug by 24%.19 This interaction could be clinically significant in patients who receive therapeutic ketamine by the oral route.

St John’s wort. In contrast to grapefruit juice, in another study of 12 healthy volunteers, St John’s wort, which induces CYP3A4, reduced the AUC of oral S-ketamine (0.3 mg/kg) by 58% and the Cmax by 66%; corresponding figures for S-norketamine were reductions by 23% and 18%, respectively.20

The studies reviewed in this section suggest the reasonable conclusion that whatever induces CYP3A4 or CYP2B6 will reduce exposure to ketamine and whatever inhibits CYP3A4 or CYP2B6 will increase exposure to ketamine; therefore, appropriate dose adjustments may be necessary so that ketamine remains effective and so that its adverse effects are not increased. This could involve some guesswork because the extent of change of exposure to ketamine in the individual patient cannot be predicted. Therefore, to the extent that such is possible, it would be better to avoid the interaction than to deal with it.

CYP2B6 Polymorphisms and Ketamine Clearance

As already observed, the CYP2B6 enzyme plays an important role in the metabolism of ketamine. The CYP2B6 gene is highly polymorphic. As a result, there is considerable interindividual variation in the expression and activity of CYP2B6. At least 28 allelic variants and subvariants of CYP2B6 (*1B through *29) have been described, some of which have been shown to influence substrate drug clearance and treatment response.21

The CYP2B6*6 allele is the most common polymorphism and is found mostly in African, African-American, and some Asian populations22; the frequency ranges from 15% to over 60%, depending on ethnicity.23 An in vitro study demonstrated that the clearance of both R- and S- enantiomers of ketamine was increased at least 2-fold and 6-fold with the CYP2B6*1/*1 wild-type genotype as compared with the CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively.24 In explanation, the CYP2B6*6 allele is associated with reduced CYP2B6 expression and activity, and homozygosity for this allele is associated with greater reduction in activity.22 The magnitude of the finding demonstrates the importance of CYP2B6 in ketamine metabolism.24

The above notwithstanding, a comparison of volunteers with CYP2B6*1/*1, *1/*6, or *6/*6 genotypes (n = 10 per group) found no differences between groups in ketamine N-demethylation, ketamine enantiomer and metabolite AUC, Cmax, apparent oral clearance, and metabolite formation clearance. There were also no differences between groups in subjective outcomes of alertness, energy level, clumsiness, confusion, anxiety, and nausea.22 A possible limitation of this study is that ketamine was administered orally in the dose of 0.4 mg/kg; given the low and variable oral bioavailability of the drug, this study may not have been adequately designed and powered to identify behavioral outcome differences between genetic polymorphisms. In this connection, another low dose (100 mg/24 h) study of a ketamine infusion in patients with chronic pain (n = 49) found a significant, dose-dependent effect of the *6 allele on ketamine concentration and clearance.25

Whereas these studies do not support firm conclusions, it is reasonable to suppose that persons with the *6 allele, especially those who are homozygous for this allele, may require lower doses of ketamine than the average patient. This lower-dose requirement may be especially noteworthy in African, African-American, and Asian patients. An alternate possibility that needs to be studied is that, in the presence of an inefficient CYP2B6 metabolic pathway, the CYP3A4 pathway will compensate; if so, the clinical impact of the 2B6 genetic variations could be small, and there may be no polymorphism-related variations in dose requirement at all.

Pharmacodynamic Interactions

Pharmacodynamic interactions with ketamine are largely intuitive and can be predicted based on the known clinical effects of ketamine and the interacting drug. Some special interactions are considered in this section.

Interactions with drugs acting on glutamatergic neurotransmission. Ketamine has a large number of biological effects, and its mechanism of antidepressant action is not known; however, it is primarily classified as a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist.26–29 In this connection, memantine, which is a fast-off, voltage-dependent, noncompetitive NMDA receptor antagonist,30 may offset some actions of ketamine. For example, memantine reduced ketamine-induced social withdrawal in a rodent model.31 However, there are no clinical reports on ketamine-memantine interactions, and the interaction, if any, may not be important because it is unlikely that a patient who requires ketamine for depression will also be receiving memantine for any on- or off-label indication.

In low doses, ketamine may increase the release of glutamate.28 Lamotrigine, which inhibits the release of glutamate,32,33 may be a part of the prescription of patients with bipolar depression. The interaction between ketamine and lamotrigine is therefore of interest. Lamotrigine appears to antagonize some of the effects of ketamine. There is a report of the failure of ketamine anesthesia in a patient with lamotrigine overdose34 and a report of the use of lamotrigine to reduce craving for and abuse of ketamine in a patient with ketamine use disorder.35 Lamotrigine was shown to protect against ketamine- but not amphetamine-induced psychosis in a murine model.36

In a randomized, placebo-controlled laboratory study37 of 16 healthy volunteers, pretreatment with lamotrigine (300 mg) attenuated many effects of intravenous ketamine administered as a bolus (0.26 mg/kg) or by infusion (0.65 mg/kg/h); these effects included perceptual abnormalities, schizophrenia-like positive and negative symptoms, and learning and memory impairment. Interestingly, lamotrigine increased the mood-elevating effect of ketamine; however, this effect was observed only at 5 minutes posttreatment with ketamine, and there was no significant interaction at later assessment points.

Clozapine may indirectly influence glutamatergic neurotransmission through action on glycine transporters.38 In a double-blind, placebo-controlled study, clozapine was shown to blunt ketamine-induced increase in positive symptoms in 10 antipsychotic-free schizophrenia patients.39 This, however, does not prove that the action of clozapine was mediated through glutamatergic modulation.

The literature reviewed in this section suggests that drugs that interfere with glutamatergic neurotransmission reduce the adverse effects of ketamine. There is no information on how the antidepressant action of ketamine may be impacted, and so, until the subject is formally studied, prudence may be desirable when combining ketamine with drugs with glutamatergic actions.

Interactions with benzodiazepines. At least in a murine model, ketamine does not affect the anticonvulsant and antinociceptive action of benzodiazepines.40 Benzodiazepines, however, may compromise the antidepressant action of ketamine. Ford et al41 observed that, in a medication-refractory patient with bipolar depression, ketamine infusions resulted in antidepressant benefits that lasted just 1–3 days; this benefit extended to up to 10–14 days when lorazepam (3.5 mg/d) was discontinued from the list of concurrent medications.

Possible attenuation of ketamine response by concurrent benzodiazepine use was also suggested by Frye et al.42 In this post hoc analysis of a 2-week trial of ketamine in patients with treatment-refractory depression, concurrent benzodiazepine use did not influence the response and remission rates; however, the mean benzodiazepine dose was observed to have been significantly higher in nonresponders (n = 2) relative to responders (n = 4) (but not in nonremitters relative to remitters). In another post hoc analysis of data from an RCT of ketamine in refractory depression, Albott et al43 found that, in comparison with patients not receiving benzodiazepines (n = 9), those receiving benzodiazepines (n = 4) took longer to respond and remit and relapsed earlier; response and remission rates, however, did not vary as a function of benzodiazepine use.

The ketamine-benzodiazepine interaction may arise from the nonspecific central depressant effect of benzodiazepines, mediated through γ-aminobutyric acid (GABA), or it may result from benzodiazepine-induced suppression of ketamine-related activation of dopamine neurons in the nucleus accumbens and striatum.44 Albott et al43 suggested another mechanism: benzodiazepines may dampen the NMDA-mediated inhibitory effect of ketamine on GABA interneurons, thereby dampening ketamine-induced increase in glutamatergic signaling through AMPA receptors.

Antidepressant drugs. Many ketamine trials that demonstrated the safety and efficacy of the drug were conducted in patients in whom concurrent antidepressant treatments were continued; this suggests that most conventional antidepressants are perhaps compatible with ketamine therapy.2

Conclusions

Ketamine is unlikely to induce clinically significant drug interactions except to the extent that these are predictable by its clinical actions. Drugs that induce or inhibit CYP2B6 and CYP3A4 may reduce or increase, respectively, the clinical effects of ketamine. Interindividual variations in CYP2B6 activity, related to genetic polymorphisms, may likewise influence the clinical effects of ketamine. Concurrent benzodiazepine medication may diminish the antidepressant benefits of ketamine; whereas drugs that inhibit glutamatergic signaling may reduce the adverse effects of ketamine, it is unknown whether the antidepressant action is also diminished. It is likely that most conventional antidepressants can be safely combined with ketamine.

REFERENCES

1. Andrade C. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action. J Clin Psychiatry. 2017;78(4):e415–e419. PubMed doi:10.4088/JCP.17f11567

2. Andrade C. Ketamine for depression, 2: diagnostic and contextual indications. J Clin Psychiatry. 2017;78(5):e555–e558. PubMed doi:10.4088/JCP.17f11629

3. Andrade C. Ketamine for depression, 3: does chirality matter?J Clin Psychiatry. 2017;78(6):e674–e677. PubMed doi:10.4088/JCP.17f11681

4. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852–e857.

5. Loch JM, Potter J, Bachmann KA. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology. 1995;50(3):146–153. PubMed doi:10.1159/000139276

6. Meneguz A, Fortuna S, Lorenzini P, et al. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. Exp Toxicol Pathol. 1999;51(4-5):392–396. PubMed doi:10.1016/S0940-2993(99)80027-X

7. Chen JT, Chen RM. Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opin Drug Metab Toxicol. 2010;6(3):273–281. PubMed doi:10.1517/17425250903505108

8. Lin F, He Y, Zhang L, et al. Assessment of the effect of ketamine on cytochrome P450 isoforms activity in rats by cocktail method. Int J Clin Exp Med. 2015;8(3):4335–4341. PubMed

9. Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 2012;15(4):400–403. PubMed doi:10.1089/jpm.2011.0314

10. Schoevers RA, Chaves TV, Balukova SM, et al. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208(2):108–113. PubMed doi:10.1192/bjp.bp.115.165498

11. Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord. 2016;204:1–8. PubMed doi:10.1016/j.jad.2016.05.076

12. Qi X, Evans AM, Wang J, et al. Inhibition of morphine metabolism by ketamine. Drug Metab Dispos. 2010;38(5):728–731. PubMed doi:10.1124/dmd.109.030957

13. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30(7):853–858. PubMed doi:10.1124/dmd.30.7.853

14. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001;29(6):887–890. PubMed

15. Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology. 2011;114(6):1435–1445. PubMed doi:10.1097/ALN.0b013e318218a881

16. Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90(2):296–302. PubMed doi:10.1038/clpt.2011.140

17. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain. 2010;14(6):625–629. PubMed doi:10.1016/j.ejpain.2009.10.003

18. Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309–316. PubMed doi:10.1503/cmaj.120951

19. Peltoniemi MA, Saari TI, Hagelberg NM, et al. S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol. 2012;68(6):979–986. PubMed doi:10.1007/s00228-012-1214-9

20. Peltoniemi MA, Saari TI, Hagelberg NM, et al. St John’s wort greatly decreases the plasma concentrations of oral S-ketamine. Fundam Clin Pharmacol. 2012;26(6):743–750. PubMed doi:10.1111/j.1472-8206.2011.00954.x

21. Mo SL, Liu YH, Duan W, et al. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 2009;10(7):730–753. PubMed doi:10.2174/138920009789895534

22. Rao LK, Flaker AM, Friedel CC, et al. Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance. Anesthesiology. 2016;125(6):1103–1112. PubMed doi:10.1097/ALN.0000000000001392

23. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. PubMed doi:10.3389/fgene.2013.00024

24. Li Y, Coller JK, Hutchinson MR, et al. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos. 2013;41(6):1264–1272. PubMed doi:10.1124/dmd.113.051631

25. Li Y, Jackson KA, Slon B, et al. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol. 2015;80(2):276–284. PubMed doi:10.1111/bcp.12614

26. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol. 2015;30:139–143. PubMed doi:10.1016/j.conb.2014.12.004

27. Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36(44):11158–11164. PubMed doi:10.1523/JNEUROSCI.1547-16.2016

28. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42(4):222–229. PubMed doi:10.1503/jpn.160175

29. Strasburger SE, Bhimani PM, Kaabe JH, et al. What is the mechanism of ketamine’s rapid-onset antidepressant effect? a concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017;42(2):147–154. PubMed doi:10.1111/jcpt.12497

30. Jarvis B, Figgitt DP. Memantine. Drugs Aging. 2003;20(6):465–476, discussion 477–478. PubMed doi:10.2165/00002512-200320060-00005

31. Uribe E, Landaeta J, Wix R, et al. Memantine reverses social withdrawal induced by ketamine in rats. Exp Neurobiol. 2013;22(1):18–22. PubMed doi:10.5607/en.2013.22.1.18

32. Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother. 2003;4(2):243–251. PubMed doi:10.1517/14656566.4.2.243

33. Hahn CG, Gyulai L, Baldassano CF, et al. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry. 2004;65(6):791–804. PubMed doi:10.4088/JCP.v65n0610

34. Kornhall D, Nielsen EW. Failure of ketamine anesthesia in a patient with lamotrigine overdose. Case Rep Crit Care. 2014;2014:916360. PubMed

35. Huang MC, Chen LY, Chen CK, et al. Potential benefit of lamotrigine in managing ketamine use disorder. Med Hypotheses. 2016;87:97–100. PubMed doi:10.1016/j.mehy.2015.11.011

36. Brody SA, Geyer MA, Large CH. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl). 2003;169(3–4):240–246. PubMed doi:10.1007/s00213-003-1421-2

37. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270–276. PubMed doi:10.1001/archpsyc.57.3.270

38. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984–997, 979. PubMed doi:10.1038/sj.mp.4001551

39. Malhotra AK, Adler CM, Kennison SD, et al. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42(8):664–668. PubMed doi:10.1016/S0006-3223(96)00546-X

40. Fidecka S, Pirogowicz E. Lack of interaction between the behavioral effects of ketamine and benzodiazepines in mice. Pol J Pharmacol. 2002;54(2):111–117. PubMed

41. Ford N, Ludbrook G, Galletly C. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. Aust N Z J Psychiatry. 2015;49(12):1227. PubMed doi:10.1177/0004867415590631

42. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336. PubMed doi:10.1097/JCP.0000000000000316

43. Albott CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–e309. PubMed doi:10.4088/JCP.16l11277

44. Irifune M, Sato T, Kamata Y, et al. Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice. Can J Anaesth. 1998;45(5 pt 1):471–478. PubMed doi:10.1007/BF03012584